Use este identificador para citar ou linkar para este item: http://repositorio.ufla.br/jspui/handle/1/41250
Registro completo de metadados
Campo DCValorIdioma
dc.creatorHashem, Anwar M.-
dc.creatorAlghamdi, Badrah S.-
dc.creatorAlgaissi, Abdullah A.-
dc.creatorAlshehri, Fahad S.-
dc.creatorBukhari, Abdullah-
dc.creatorAlfaleh, Mohamed A.-
dc.creatorMemish, Ziad A.-
dc.date.accessioned2020-05-27T15:11:31Z-
dc.date.available2020-05-27T15:11:31Z-
dc.date.issued2020-
dc.identifier.citationHASHEM, A. M. et al. Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: a narrative review. Travel Medicine and Infectious Disease, [S.l.], 2020. No prelo.pt_BR
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S1477893920302143pt_BR
dc.identifier.urihttp://repositorio.ufla.br/jspui/handle/1/41250-
dc.description.abstractThe rapidly spreading Coronavirus Disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2), represents an unprecedented serious challenge to the global public health community. The extremely rapid international spread of the disease with significant morbidity and mortality made finding possible therapeutic interventions a global priority. While approved specific antiviral drugs against SARS-CoV-2 are still lacking, a large number of existing drugs are being explored as a possible treatment for COVID-19 infected patients. Recent publications have re-examined the use of Chloroquine (CQ) and/or Hydroxychloroquine (HCQ) as a potential therapeutic option for these patients. In an attempt to explore the evidence that supports their use in COVID-19 patients, we comprehensively reviewed the previous studies which used CQ or HCQ as an antiviral treatment. Both CQ and HCQ demonstrated promising in vitro results, however, such data have not yet been translated into meaningful in vivo studies. While few clinical trials have suggested some beneficial effects of CQ and HCQ in COVID-19 patients, most of the reported data are still preliminary. Given the current uncertainty, it is worth being mindful of the potential risks and strictly rationalise the use of these drugs in COVID-19 patients until further high quality randomized clinical trials are available to clarify their role in the treatment or prevention of COVID-19.pt_BR
dc.languageen_USpt_BR
dc.publisherElsevierpt_BR
dc.rightsrestrictAccesspt_BR
dc.sourceTravel Medicine and Infectious Diseasept_BR
dc.subjectSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)pt_BR
dc.subjectCOVID-19pt_BR
dc.subjectChloroquinept_BR
dc.subjectHydroxychloroquinept_BR
dc.titleTherapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: a narrative reviewpt_BR
dc.typeArtigopt_BR
Aparece nas coleções:FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19)

Arquivos associados a este item:
Não existem arquivos associados a este item.


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.